.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Christopher M. Jensen

Vortrag

09.12.2022
15:30 – 15:35 3 Min. 2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40 – 15:45 3 Min. 2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine

Weitere Beteiligungen

09.12.2022
15:30 – 15:35 3 Min. 2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40 – 15:45 3 Min. 2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:40 – 16:45 3 Min. 2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:45 – 16:50 3 Min. 2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine